Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation

European Journal of Pharmacology

Volumn 451, Issue 3, 2002, Pages 327-333

  Nishikori, Tomohiro ^a   Irie, Kaoru ^a   Suganuma, Taiyo ^a   Ozaki, Makoto ^a   Yoshioka, Toshimasa ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Carrageenan; FR167653; Lipopolysaccharide; p38 MAP (mitogen activated protein) kinase inhibitor; Paw edema; Vascular permeability

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE SULFATE MONOHYDRATE; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CARRAGEENAN; CYCLOOXYGENASE 2; FRI 67653; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; INFLAMMATION; INJECTION SITE; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; EDEMA; INFLAMMATION; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037144228     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02238-0     Document Type: Article

References (23)

1. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279:1996;1453-1461.
2. Badger A.M., Cook M.N., Lark M.W., Newman-Tarr T.M., Swift B.A., Nelson A.H., Barone F.C., Kumar S. SB203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161:1998;467-473.
3. Escott K.J., Belvisi M.G., Birrell M.A., Webber S.E., Foster M.L., Sargent C.A. Effect of the p38 kinase inhibitor, SB203580, on allergic airway inflammation in the rat. Br. J. Pharmacol. 131:2000;173-176.
4. 2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1β-treated human synovial fibroblasts. J. Biol. Chem. 276:2001;31720-31731.
5. Fujii E., Irie K., Uchida Y., Tsukahara F., Muraki T. Possible role of nitric oxide in 5-hydroxytryptamine-induced increase in vascular permeability in mouse skin. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;361-364.
6. Fujii E., Irie K., Ogawa A., Ohba K., Muraki T. Role of nitric oxide and prostaglandins in lipopolysaccharide-induced increase in vascular permeability in mouse skin. Eur. J. Pharmacol. 297:1996;257-263.
7. Fujii E., Yoshioka T., Ishida H., Irie K., Muraki T. Evaluation of iNOS-dependent and independent mechanisms of the microvascular permeability change induced by lipopolysaccharide. Br. J. Pharmacol. 130:2000;90-94.
8. Han J., Lee J.-D., Bibbs L., Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:1994;808-811.
9. Hatanaka K., Kawamura M., Murai N., Ogino M., Majima M., Ogino K., Harada Y. FR167653, a cytokine synthesis inhibitor, exhibits anti-inflammatory effects early in rat carrageenin-induced pleurisy but no effect later. J. Pharmacol. Exp. Ther. 299:2001;519-527.
10. Irie K., Fujii E., Ishida H., Wada K., Suganuma T., Nishikori T., Yoshioka T., Muraki T. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br. J. Pharmacol. 133:2001;237-242.
11. Lee J.C., Badger A.M., Griswold D.E., Dunnington D., Truneh A., Votta B., White J.R., Young P.R., Bender P.E. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. N.Y. Acad. Sci. 696:1993;149-170.
12. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746.
13. McGinty A., Foschi M., Chang Y.-W.E., Han J., Dunn M.J., Sorokin A. Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades. Biochem. J. 352:2000;419-424.
14. Nantel F., Denis D., Gordon R., Northey A., Cirino M., Metters K.M., Chan C.C. Distribution and regulation of cyclooxygenase-2 in carrageenin-induced inflammation. Br. J. Pharmacol. 128:1999;853-859.
15. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12013-12017.
16. Sekut L., Menius J.A. Jr., Brackeen M.F., Connolly K.M. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J. Lab. Clin. Med. 124:1994;813-820.
17. Takahashi S., Keto Y., Fujita T., Uchiyama T., Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J. Pharmacol. Exp. Ther. 296:2001;48-56.
18. Ueno A., Naraba H., Oh-ishi S. Mouse paw edema induced by a novel bradykinin agonist and its inhibition by B2-antagonist. Jpn. J. Pharmacol. 78:1998;109-111.
19. Yamamoto N., Sakai F., Yamazaki H., Narahara K., Okuhara M. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur. J. Pharmacol. 314:1996;137-142.
20. Yamamoto N., Sakai F., Yamazaki H., Sato N., Narahara K., Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock. Eur. J. Pharmacol. 327:1997;169-175.
21. Wada K., Fujii E., Ishida H., Yoshioka T., Muraki T. Effect of lipoteichoic acid on dermal vascular permeability in mice. J. Pharmacol. Exp. Ther. 294:2000;280-286.
22. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79:1999;143-180.
23. 2 production. J. Pharmacol. Exp. Ther. 283:1997;1069-1075.